Adhesion to fibronectin induces p27Kip1 nuclear accumulation through down-regulation of Jab1 and contributes to cell adhesion-mediated drug resistance (CAM-DR) in RPMI 8,226 cells

[1]  K. Nakayama,et al.  Phosphorylation of p27Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. , 2015, The Journal of Biological Chemistry.

[2]  Deepa Naishadham,et al.  Cancer statistics for Hispanics/Latinos, 2012 , 2012, CA: a cancer journal for clinicians.

[3]  Q. Ni,et al.  Expression of Spy1 protein in human Non-Hodgkin’s Lymphomas is correlated with phosphorylation of p27Kip1 on Thr187 and cell proliferation , 2012, Medical Oncology.

[4]  Chun Cheng,et al.  EXPRESSION OF CRM1 IN HUMAN GLIOMAS AND ITS SIGNIFICANCE IN P27 EXPRESSION AND CLINICAL PROGNOSIS , 2009, Neurosurgery.

[5]  W. Dalton,et al.  HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma , 2008, British journal of haematology.

[6]  Kenneth C. Anderson,et al.  Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets , 2007, Nature Reviews Cancer.

[7]  W. Dalton,et al.  Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. , 2006, Blood.

[8]  K. Nakayama,et al.  Ubiquitin ligases: cell-cycle control and cancer , 2006, Nature Reviews Cancer.

[9]  R. Kyle,et al.  Drug therapy: Multiple myeloma , 2004 .

[10]  D. Lane,et al.  Mdm2-Mediated NEDD8 Conjugation of p53 Inhibits Its Transcriptional Activity , 2004, Cell.

[11]  F. Esteva,et al.  Expression of cell cycle inhibitor p27Kip1 and its inactivator Jab1 in melanocytic lesions , 2004, Modern Pathology.

[12]  J. Kato,et al.  Prognostic significance of localized p27Kip1 and potential role of Jab1/CSN5 in pancreatic cancer. , 2004, Oncology reports.

[13]  K. Nakashiro,et al.  Skp2 and Jab1 Expression Are Associated with Inverse Expression of p27KIP1 and Poor Prognosis in Oral Squamous Cell Carcinomas , 2003, Oncology.

[14]  L. Pusztai,et al.  Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  H. Nakamine,et al.  Jun activation domain-binding protein 1 expression in malignant lymphoma of the thyroid: its linkage to degree of malignancy and p27 expression. , 2003, Anticancer research.

[16]  H. Kuroda,et al.  Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia , 2003, Nature Medicine.

[17]  A. Miyauchi,et al.  14-3-3 sigma possibly plays a constitutive role in papillary carcinoma, but not in follicular tumor of the thyroid. , 2003, Cancer letters.

[18]  C. Kittas,et al.  Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1). , 2003, Cancer research.

[19]  T. McDonnell,et al.  Expression of p27Kip1 and c-Jun Activation Binding Protein 1 Are Inversely Correlated in Systemic Anaplastic Large Cell Lymphoma , 2003 .

[20]  E. Lam,et al.  Jab1 Co-activation of c-Jun Is Abrogated by the Serine 10-phosphorylated Form of p27Kip1 * , 2002, The Journal of Biological Chemistry.

[21]  M. Takagi,et al.  Expression of Cyclin‐dependent Kinase Inhibitor p27/Kipl and AP‐1 Coactivator p38/Jabl Correlates with Differentiation of Embryonal Rhabdomyosarcoma , 2002, Japanese journal of cancer research : Gann.

[22]  Minoru Yoshida,et al.  The Cytoplasmic Shuttling and Subsequent Degradation of p27Kip1 Mediated by Jab1/CSN5 and the COP9 Signalosome Complex* , 2002, The Journal of Biological Chemistry.

[23]  L. Di Marcotullio,et al.  p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis , 2001, The EMBO journal.

[24]  Y. Dong,et al.  Jab1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial ovarian tumors. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  C. Schwechheimer,et al.  COP9 signalosome revisited: a novel mediator of protein degradation. , 2001, Trends in cell biology.

[26]  D. Graham,et al.  The analysis of costimulatory receptor signaling cascades in normal T lymphocytes using in vitro gene transfer and reporter gene analysis , 2001, Nature Medicine.

[27]  K. Anderson,et al.  Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. , 2001, Blood.

[28]  C J Kemp,et al.  p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. , 2001, Experimental cell research.

[29]  D. Chamovitz,et al.  JAB1/CSN5 and the COP9 signalosome , 2001, EMBO reports.

[30]  S. Reed,et al.  Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. , 2000, Current opinion in cell biology.

[31]  W. Dalton,et al.  Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR) , 2000, Oncogene.

[32]  M. Kitagawa,et al.  Phosphorylation at Serine 10, a Major Phosphorylation Site of p27 Kip1 , Increases Its Protein Stability* , 2000, The Journal of Biological Chemistry.

[33]  W. Dalton,et al.  Integrin-Mediated Drug Resistance in Multiple Myeloma , 2000, Leukemia & lymphoma.

[34]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[35]  J. Kato,et al.  Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1 , 1999, Nature.

[36]  K. Nakayama,et al.  Cip/Kip cyclin‐dependent kinase inhibitors: brakes of the cell cycle engine during development , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.

[37]  James M. Roberts,et al.  The murine gene p27Kip1 is haplo-insufficient for tumour suppression , 1998, Nature.

[38]  Bruno Amati,et al.  Phosphorylation‐dependent degradation of the cyclin‐dependent kinase inhibitor p27Kip1 , 1997, The EMBO journal.

[39]  James M. Roberts,et al.  Cyclin E-CDK2 is a regulator of p27Kip1. , 1997, Genes & development.

[40]  James M. Roberts,et al.  Requirement of p27Kip1 for Restriction Point Control of the Fibroblast Cell Cycle , 1996, Science.

[41]  T. Libermann,et al.  Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. , 1996, Blood.

[42]  P. Beer-Romero,et al.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. , 1995, Science.

[43]  A. Iavarone,et al.  Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. , 1995, Genes & development.

[44]  James M. Roberts,et al.  lnterleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin , 1994, Nature.

[45]  James M. Roberts,et al.  Cloning of p27 Kip1 , a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals , 1994, Cell.

[46]  Tony Hunter,et al.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21 , 1994, Cell.

[47]  K. Rai,et al.  The frequency of long‐term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow‐up time of 6 years , 1989, British journal of haematology.

[48]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[49]  W. Dalton,et al.  Mechanisms Associated with cell Adhesion Mediated Drug Resistance (CAM-DR) in Hematopoietic Malignancies , 2004, Cancer and Metastasis Reviews.

[50]  T. McDonnell,et al.  Expression of p27(Kip1) and c-Jun activation binding protein 1 are inversely correlated in systemic anaplastic large cell lymphoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  A. Miyauchi,et al.  14-3-3 sigma possibly plays a constitutive role in papillary carcinoma, but not in follicular tumor of the thyroid. , 2003, Cancer letters.

[52]  D. Chamovitz.  A complex situation , 2001 .

[53]  R. Jove,et al.  Multiple Myeloma: New Insights and Therapeutic Approaches. , 2000, Hematology. American Society of Hematology. Education Program.

[54]  J. Slingerland,et al.  The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. , 1999, Annual review of medicine.

[55]  W. Dalton,et al.  Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. , 1999, Blood.

[56]  R. Larson,et al.  Protooncogene expression and the clinical characteristics of acute nonlymphocytic leukemia: A Leukemia Intergroup pilot study. , 1989, Blood.

[57]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.